Study Of Dongbei Pharmaceutical Company's Financial Risk Control Strategies

With the deepening of the national health care reform, pharmaceutical production and management of enterprises by the direct impact, so the analysis of financial risks pharmaceutical production enterprises, have complete control of the financial situation of pharmaceutical companies has become a financial risk control, to maintain normal business operations key.This study is aimed at such a background, the DB Pharmaceutical companies in the specific case study on DB Pharmaceutical company financial risk conducted a comprehensive analysis, in the course of this study, first, for the theory of financial risk management are described details of the relevant principles and methods of financial risk management, risk identification were studied. And on the basis of theoretical analysis, combined with industry focus, the in-depth study of the risk status of the financial indicators DB Pharmaceutical Company, through this study can be seen that the current short-term solvency DB Pharmaceutical company is weak, the overall level of both ROE is very low, capital stock occupied more inventory turnover slow, weak liquidity assets, cash recovery time required rather long recovery of funds accounted for a lower proportion of the funds to pay a large part of the funds still occupied, most likely to face losses, although effective by way of internal financing of part of the bank repayment pressure, but the financial risk has not been fully lifted. Analyze the reasons for its formation is not only influenced by the national health reform policy at the same time with the main due to internal reasons companies, mainly in the financial authorization system is imperfect, internal audit in name only, and for the implementation of the overall budget and other reasons have led to the company's financial risk happened. For such problems, this paper should establish the system of authorization and approval system, designed to strengthen the internal independence, strengthen the construction of financial information, the implementation of a comprehensive budget management, build a scientific incentive and restraint mechanisms, improve financial risk early warning mechanism measures.Through this study, not only fully aware of the DB Pharmaceutical company's current financial risk, but also for decision-makers for the current financial venture, to develop a reasonable response to the financial risk has played a reference and reference value.